These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 766682)

  • 1. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.
    Mitchell JR; Zimmerman HJ; Ishak KG; Thorgeirsson UP; Timbrell JA; Snodgrass WR; Nelson SD
    Ann Intern Med; 1976 Feb; 84(2):181-92. PubMed ID: 766682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.
    Mitchell JR; Thorgeirsson UP; Black M; Timbrell JA; Snodgrass WR; Potter WZ; Jollow HR; Keiser HR
    Clin Pharmacol Ther; 1975 Jul; 18(1):70-9. PubMed ID: 1149365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.
    Mitchell JR; Long MW; Thorgeirsson UP; Jollow DJ
    Chest; 1975 Aug; 68(2):181-90. PubMed ID: 1080096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
    Grönhagen-Riska C; Hellstrom PE; Fröseth B
    Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical hepatotoxicity of isoniazid in children.
    Stein MT; Liang D
    Pediatrics; 1979 Oct; 64(4):499-505. PubMed ID: 492816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo.
    Timbrell JA; Mitchell JR; Snodgrass WR; Nelson SD
    J Pharmacol Exp Ther; 1980 May; 213(2):364-9. PubMed ID: 6767840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.
    Sarma GR; Immanuel C; Kailasam S; Narayana AS; Venkatesan P
    Am Rev Respir Dis; 1986 Jun; 133(6):1072-5. PubMed ID: 3717759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary metabolic profile of isoniazid in patients who develop isoniazid-related liver damage.
    Timbrell JA; Wright JM
    Hum Toxicol; 1984 Dec; 3(6):485-95. PubMed ID: 6526396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoniazid-associated hepatitis. Report of an outbreak.
    Garibaldi RA; Drusin RE; Ferebee SH; Gregg MB
    Am Rev Respir Dis; 1972 Sep; 106(3):357-65. PubMed ID: 5080707
    [No Abstract]   [Full Text] [Related]  

  • 10. Isoniazid-associated hepatitis in 114 patients.
    Black M; Mitchell JR; Zimmerman HJ; Ishak KG; Epler GR
    Gastroenterology; 1975 Aug; 69(2):289-302. PubMed ID: 1150039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidation of hydrazine metabolites formed from isoniazid.
    Lauterburg BH; Smith CV; Todd EL; Mitchell JR
    Clin Pharmacol Ther; 1985 Nov; 38(5):566-71. PubMed ID: 3931954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.
    Lauterburg BH; Smith CV; Todd EL; Mitchell JR
    J Pharmacol Exp Ther; 1985 Dec; 235(3):566-70. PubMed ID: 4078724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
    Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
    Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isoniazid-related hepatotoxicity: a study of the effect of rifampicin administration on the metabolism of acetylisoniazid in man.
    Jenner PJ; Ellard GA
    Tubercle; 1989 Jun; 70(2):93-101. PubMed ID: 2617692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.
    Gurumurthy P; Krishnamurthy MS; Nazareth O; Parthasarathy R; Sarma GR; Somasundaram PR; Tripathy SP; Ellard GA
    Am Rev Respir Dis; 1984 Jan; 129(1):58-61. PubMed ID: 6367570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical consequences of polymorphic acetylation of basic drugs.
    Drayer DE; Reidenberg MM
    Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].
    Ellard GA
    Rev Mal Respir; 1984; 1(4):207-19. PubMed ID: 6505358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat.
    Nelson SD; Mitchell JR; Timbrell JA; Snodgrass WR; Corcoran GB
    Science; 1976 Sep; 193(4256):901-3. PubMed ID: 7838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid hepatitis.
    Maddrey WC; Boitnott JK
    Ann Intern Med; 1973 Jul; 79(1):1-12. PubMed ID: 4721174
    [No Abstract]   [Full Text] [Related]  

  • 20. [The influence of rifampicin upon the metabolism of isoniazid (author's transl)].
    Modai J; Coulaud JP; Vivien JM; Berthelot G; Bergogne-Berezin E
    Nouv Presse Med; 1978 Apr; 7(15):1263-7. PubMed ID: 662655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.